Ancient herb meets modern painkiller in battle against chronic prostatitis pain
NCT ID NCT06159114
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This trial tests whether Ningmitai, a traditional Chinese medicine used for urinary issues, can reduce pelvic pain in men with chronic prostatitis. About 240 men aged 18-60 with long-term pelvic discomfort will receive either Ningmitai alone, the painkiller celecoxib alone, or both for 6 weeks. The goal is to see if the herbal capsule, alone or combined, outperforms celecoxib in easing pain.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ningmitai capsule, a traditional Chinese medicine, alone or combined with celecoxib
- What this could lead to
- If effective, Ningmitai could offer a new option for managing chronic pelvic pain in men with prostatitis, possibly reducing reliance on standard painkillers.
- What could go wrong
- This is a Phase 4 trial with 240 participants, so results may not apply broadly. Ningmitai is a traditional remedy with limited modern evidence, and celecoxib carries risks like stomach bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
242 people
The number who actually took part.
- Started
-
Dec 2023
- Finished
-
Jan 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age: male patients aged 18-60 years; 2. Long-term and repeated pelvic discomfort or pain (NIH-CPSI pain score ≥ 4 points), lasting more than 3 months, may be accompanied by different degrees of urination symptoms and sexual dysfunction; 3. Negative bacterial in urine before and after prostate massage; 4. Voluntarily participate in the trial and agree to sign an informed consent form. Exclusion Criteria: 1. Use any non-steroidal anti-inflammatory drugs,α receptor blockers,antibiotics, PDE5 inhibitors or other traditional Chinese medicines or botanicals for the treatment of prostatitis in the past 2 weeks; those who are using drugs for the treatment of prostatitis need to stop the drug for 2 weeks before the clinical trial; 2. Patients who have received prostate surgery and treatment such as TURP, TUIP, open prostatectomy, biofeedback therapy, hyperthermia, ablation, prostate cryotherapy, transperineal extracorporeal shock wave therapy, prostate injection therapy, transurethral prostate perfusion therapy, or bladder surgery such as bladder neck incision; 3. Urine WBC ≥ 5 /HP, urinary system infection within 3 months; 4. Pelvic pain and voiding dysfunction caused by non-prostatitis factors, such as benign prostatic hyperplasia, diseases of testis, epididymis and spermatic cord, overactive bladder, neurogenic bladder, interstitial cystitis, glandular cystitis, sexually transmitted diseases, bladder tumor, prostate cancer, anorectal disease, lumbar disease, central and peripheral neuropathy; 5. Suffering from serious primary cardiovascular disease, liver disease, kidney disease, hematological disease, lung disease or other serious diseases such as tumors or AIDS; 6. Significant adverse events in clinical or laboratory examination indicators, such as ALT and AST ≥ 1.5 times the upper limit of reference value, creatinine (SCR) \> the upper limit of reference value; 7. Allergic to the components of the test drugs or sulfa; 8. Previous active peptic ulcer / bleeding; 9. A birth plan within the past 8 months; 10. Legally disabled patients (blind, deaf, mute, intellectual disability, etc.), psychiatric patients; 11. Suspected or confirmed alcohol or drug abuse, or other conditions that reduce the possibility of enrollment or complicate enrollment according to the judgment of the investigator, such as frequent changes in the working environment that are likely to cause loss to follow-up; 12. Participating in other clinical trials; 13. Considered unsuitable for enrollment by the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic prostatitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.